التفاصيل البيبلوغرافية
| العنوان: |
Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure |
| المؤلفون: |
Dennis D. Wang, Anna V. Naumova, Daniel Isquith, Jamie Sapp, Kim A. Huynh, Isabella Tucker, Niranjan Balu, Anna Voronyuk, Baocheng Chu, Karen Ordovas, Charles Maynard, Rong Tian, Xue-Qiao Zhao, Francis Kim |
| المصدر: |
Cardiovascular Diabetology, Vol 23, Iss 1, Pp 1-9 (2024) |
| بيانات النشر: |
BMC, 2024. |
| سنة النشر: |
2024 |
| المجموعة: |
LCC:Diseases of the circulatory (Cardiovascular) system |
| مصطلحات موضوعية: |
Type 2 diabetes, Inflammation, IL-1B, PBMC respiration, CMRI, Cardiac fibrosis, Diseases of the circulatory (Cardiovascular) system, RC666-701 |
| الوصف: |
Abstract Objective Sodium glucose cotransporter 2 (SGLT2) inhibitors significantly improve cardiovascular outcomes in diabetic patients; however, the mechanism is unclear. We hypothesized that dapagliflozin improves cardiac outcomes via beneficial effects on systemic and cardiac inflammation and cardiac fibrosis. Research and design methods This randomized placebo-controlled clinical trial enrolled 62 adult patients (mean age 62, 17% female) with type 2 diabetes (T2D) without known heart failure. Subjects were randomized to 12 months of daily 10 mg dapagliflozin or placebo. For all patients, blood/plasma samples and cardiac magnetic resonance imaging (CMRI) were obtained at time of randomization and at the end of 12 months. Systemic inflammation was assessed by plasma IL-1B, TNFα, IL-6 and ketone levels and PBMC mitochondrial respiration, an emerging marker of sterile inflammation. Global myocardial strain was assessed by feature tracking; cardiac fibrosis was assessed by T1 mapping to calculate extracellular volume fraction (ECV); and cardiac tissue inflammation was assessed by T2 mapping. Results Between the baseline and 12-month time point, plasma IL-1B was reduced (− 1.8 pg/mL, P = 0.003) while ketones were increased (0.26 mM, P = 0.0001) in patients randomized to dapagliflozin. PBMC maximal oxygen consumption rate (OCR) decreased over the 12-month period in the placebo group but did not change in patients receiving dapagliflozin (− 158.9 pmole/min/106 cells, P = 0.0497 vs. − 5.2 pmole/min/106 cells, P = 0.41), a finding consistent with an anti-inflammatory effect of SGLT2i. Global myocardial strain, ECV and T2 relaxation time did not change in both study groups. Clinical Trial.gov Registration NCT03782259. |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
1475-2840 |
| Relation: |
https://doaj.org/toc/1475-2840 |
| DOI: |
10.1186/s12933-024-02294-z |
| URL الوصول: |
https://doaj.org/article/9cccd8e7a351412db0fdd48cd088f27f |
| رقم الانضمام: |
edsdoj.9cccd8e7a351412db0fdd48cd088f27f |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder